Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 222 bp insertion in exon 2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ELK1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ELK1 also known as ELK-1 or ETS-domain protein ELK1 is a transcription factor involved in regulating gene expression. It is a member of the ETS family of transcription factors and has a molecular mass of approximately 54 kDa. ELK1 is mainly expressed in the nucleus of cells and plays a significant role in various tissues by interacting with other proteins. It has sequence-specific DNA-binding ability which allows it to influence the transcription of target genes.
Biological function summary
ELK1 functions in the regulation of gene expression related to cellular proliferation and differentiation. It often forms a ternary complex with serum response factor (SRF) on serum response elements (SREs) to modulate the transcriptional responses of genes important for cell growth. The activation of ELK1 is phosphorylation-dependent primarily by mitogen-activated protein kinases (MAPKs) which further facilitates its role as a transcription regulator. This phosphorylation increases the transcriptional activity enabling ELK1 to actively participate in cellular responses to external signals.
Pathways
ELK1 participates prominently in the MAPK/ERK signaling pathway and the JNK signaling pathway. Through these pathways ELK1 gets activated influencing the transcription of immediate early genes responsible for cell cycle progression and apoptosis. ELK1 interacts with other proteins in these pathways such as MEK and ERK leading to a coordinated response to growth signals. These interactions underline its importance in signal transduction processes and cellular response mechanisms.
ELK1 has associations with certain cancers and neurodegenerative disorders. In particular its dysregulation has been noted in the context of breast cancer where ELK1 is implicated in abnormal cell proliferation. Similarly in neurodegenerative diseases like Alzheimer's ELK1's altered activity levels can affect neuron function and survival. Other proteins such as amyloid precursor protein in Alzheimer's or estrogen receptor in breast cancer connect with ELK1 influencing disease progression through complex signaling networks.
